PRC
NTLA icon

Pearl River Capital’s Intellia Therapeutics NTLA Stock Holding History

Pearl River Capital’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-13,902
Closed -$424K – 618
2023
Q4 		$424K Buy
+13,902
New +$400K 0.07% 348
2019
Q1 		– Sell
-915
Closed -$12K – 642
2018
Q4 		$12K Buy
+915
New +$17K 0.06% 480

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Pearl River Capital's NTLA Position: Q1 2024 in Review

Pearl River Capital sold out of Intellia Therapeutics (NTLA) in Q1 2024, closing a stake of 13,902 shares — an estimated $424K sold.

Pearl River Capital first reported a position in NTLA in Q4 2018 and held it in 2 quarters. The position peaked at $424K in Q4 2023. 284 funds tracked by Wall St. Rank hold NTLA as of Q1 2024.

  • Pearl River Capital reported no remaining Intellia Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Pearl River Capital sold 13,902 Intellia Therapeutics shares in Q1 2024, an estimated $424K.
  • Pearl River Capital first reported a position in Intellia Therapeutics in Q4 2018 and held it in 2 quarters.
  • Pearl River Capital's Intellia Therapeutics position peaked at $424K in Q4 2023.
  • 284 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q1 2024.

Based on Pearl River Capital's 13F filing for Q1 2024, filed 14 May 2024.